Iopofosine-131 acquired FDA breakthrough standing for relapsed or refractory Waldenstrom macroglobulinemia, displaying robust response charges in early trials.
The U.S. Meals and Drug Administration (FDA) has granted breakthrough remedy designation to iopofosine-131, a possible first-in-class cancer-targeting agent, for the therapy of relapsed or refractory Waldenstrom macroglobulinemia (r/r WM), based on a information launch from Cellectar Biosciences.
“The FDA’s breakthrough remedy designation underscores the potential of iopofosine I-131 as it could provide substantial enchancment on a minimum of one clinically important endpoint over accessible therapies to deal with the substantial unmet medical want on this life-threatening most cancers,” mentioned James Caruso, president and chief govt officer of Cellectar, within the information launch. “With strong scientific knowledge, a positive security profile, expedited assessment designations in the USA and Europe and a compelling industrial market potential, we consider iopofosine I-131 represents a beautiful candidate for potential collaborations or companions looking for impactful innovation and accelerated growth pathways.”
Outcomes from the section 2 CLOVER WaM examine confirmed an general response charge of 83.6% and a serious response charge (MRR) of 58.2%, exceeding the examine’s major endpoint of a 20% MRR. These knowledge have been shared at a podium presentation on the 66th American Society of Hematology Annual Assembly in December 2024 by Dr. Sikander Ailawadhi, professor of drugs at Mayo Clinic.
The FDA beforehand granted iopofosine-131 each quick monitor and orphan drug designations. In Europe, the European Medicines Company (EMA) granted orphan drug designation in addition to PRIME designation for r/r WM.
Cellectar has additionally submitted a complete knowledge package deal to the EMA, together with preclinical, regulatory and manufacturing knowledge, together with security and efficacy findings from the CLOVER WaM section 2b examine. The EMA will consider whether or not the proof is ample for Cellectar to pursue conditional advertising and marketing authorization. A suggestion from the company relating to whether or not to submit a advertising and marketing authorization utility is anticipated in late July 2025.
Iopofosine I-131 makes use of a phospholipid ether as a radioconjugate monotherapy.
Cellectar’s merchandise at the moment being evaluated by well being companies contains iopofosine I-131, a phospholipid drug conjugate (PDC) delivering iodine-131; CLR 121225, an actinium-225–primarily based agent in growth for strong tumors similar to pancreatic most cancers; and CLR 121125, an iodine-125–primarily based radiotherapeutic being explored in strong tumors like triple-negative breast, lung and colorectal cancers. The corporate can be advancing proprietary preclinical PDC chemotherapy candidates and several other partnered packages.
Iopofosine I-131 can be being studied in section 2b trials for relapsed or refractory a number of myeloma and central nervous system lymphoma, in addition to within the section 1b CLOVER-2 trial for pediatric sufferers with high-grade gliomas. If accepted for the pediatric indication, Cellectar might obtain a pediatric assessment voucher from the FDA.
Altogether, the drug has acquired six orphan drug, 4 uncommon pediatric illness and two quick monitor designations from the FDA throughout a number of indications.
What Are WM and Breakthrough Remedy Designation?
WM, the most typical subtype of lymphoplasmacytic lymphoma, stays incurable with present therapies, based on the Worldwide Waldenstrom’s Macroglobulinemia Basis. Restricted accepted remedies spotlight the necessity for novel therapies with distinctive mechanisms of motion.
Breakthrough remedy designation is an FDA program designed to hurry the event and assessment of medication for severe or life-threatening circumstances. It’s granted when early scientific proof signifies that the remedy might considerably enhance a minimum of one significant endpoint over accessible remedies. This designation supplies higher interplay with the FDA and will assist a six-month precedence assessment of a future new drug utility.
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
